Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:52:50.488Z.
Calculation as of: 2026-10-06T16:52:50.488Z.
Quote observation: 2026-10-06T16:42:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.57M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.57M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.10M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.25M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.65M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.78M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
